Zihe et al., 2016 - Google Patents
Preliminary Study of Differentially Expressed Serum Peptides of Advanced NSCLC Patients Responsive to EGFR-TKI and Their Clinical SignificanceZihe et al., 2016
- Document ID
- 6895514734512752632
- Author
- Zihe W
- Chuanhao T
- Yi L
- Bin X
- Haifeng Q
- Yangyang L
- Hongjun G
- He K
- Xiaoqing L
- Publication year
- Publication venue
- Zhongguo Fei Ai Za Zhi
External Links
Snippet
背景与目的 本研究旨在应用基质辅助激光解析离子化-时间飞行质谱仪 (matrix-assisted laser desorption ionization time-of-flight mass spectrometry, MALDI-TOF-MS) 检测晚期非小细胞肺癌 (non-small cell lung cancer, NSCLC) 患者在接受表皮生长因子受体酪 …
- 201000005244 lung non-small cell carcinoma 0 title abstract description 11
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ng et al. | Integrative proteogenomic characterization of hepatocellular carcinoma across etiologies and stages | |
| Jones et al. | Circulating biomarkers for glioma: a review | |
| Chen et al. | Novel mutations on EGFR Leu792 potentially correlate to acquired resistance to osimertinib in advanced NSCLC | |
| Locasale et al. | Metabolomics of human cerebrospinal fluid identifies signatures of malignant glioma | |
| Zhu et al. | Targeted serum metabolite profiling and sequential metabolite ratio analysis for colorectal cancer progression monitoring | |
| Zhao et al. | Metabolomics profiling in plasma samples from glioma patients correlates with tumor phenotypes | |
| Lazzari et al. | Changes in plasma mass-spectral profile in course of treatment of non-small cell lung cancer patients with epidermal growth factor receptor tyrosine kinase inhibitors | |
| Xie et al. | Lowered circulating aspartate is a metabolic feature of human breast cancer | |
| Wang et al. | Clinical significance of pretreatment plasma biomarkers in advanced non-small cell lung cancer patients | |
| Cala et al. | Urinary metabolite and lipid alterations in Colombian Hispanic women with breast cancer: A pilot study | |
| Gao et al. | Tissue amino acid profile could be used to differentiate advanced adenoma from colorectal cancer | |
| US20150285817A1 (en) | Method for treating and identifying lung cancer patients likely to benefit from EGFR inhibitor and a monoclonal antibody HGF inhibitor combination therapy | |
| CN102770760A (en) | Cancer patient selection for administration of therapeutic agents using mass spectral analysis | |
| CA2744394A1 (en) | Selection of colorectal cancer patients for treatment with drugs targeting egfr pathway | |
| Aguiar-Bujanda et al. | Neutrophil to lymphocyte ratio as a prognostic factor in European patients with epidermal growth factor receptor-mutant non-small cell lung cancer treated with tyrosine kinase inhibitors | |
| Zhang et al. | Preliminary characterizations of a serum biomarker for sarcoidosis by comparative proteomic approach with tandem-mass spectrometry in ethnic Han Chinese patients | |
| Liu et al. | Efficacy of epidermal growth factor receptor–tyrosine kinase inhibitors for lung squamous carcinomas harboring EGFR mutation: A multicenter study and pooled analysis of published reports | |
| Villaruz et al. | Temsirolimus therapy in a patient with lung adenocarcinoma harboring an FBXW7 mutation | |
| Lobb et al. | An epithelial-to-mesenchymal transition induced extracellular vesicle prognostic signature in non-small cell lung cancer | |
| Sun et al. | Integration of metabolomics and machine learning revealed tryptophan metabolites are sensitive biomarkers of pemetrexed efficacy in non‐small cell lung cancer | |
| Jin et al. | Hormonal factors in association with lung cancer among Asian women: a pooled analysis from the International Lung Cancer Consortium | |
| Myers et al. | Low-frequency KRAS mutations are prevalent in lung adenocarcinomas | |
| Wang et al. | Analyzing epidermal growth factor receptor mutation status changes in advanced non‐small‐cell lung cancer at different sampling time‐points of blood within one day | |
| Tang et al. | Proteomics study of colorectal cancer and adenomatous polyps identifies TFR1, SAHH, and HV307 as potential biomarkers for screening | |
| Zhao et al. | High expression of E-cadherin in pleural effusion cells predicts better prognosis in lung adenocarcinoma patients |